Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

  1. Vrdoljak, E.
  2. Marschner, N.
  3. Zielinski, C.
  4. Gligorov, J.
  5. Cortes, J.
  6. Puglisi, F.
  7. Aapro, M.
  8. Fallowfield, L.
  9. Fontana, A.
  10. Inbar, M.
  11. Kahan, Z.
  12. Welt, A.
  13. Lévy, C.
  14. Brain, E.
  15. Pivot, X.
  16. Putzu, C.
  17. González Martín, A.
  18. de Ducla, S.
  19. Easton, V.
  20. von Minckwitz, G.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2016

Alea: 27

Zenbakia: 11

Orrialdeak: 2046-2052

Mota: Artikulua

DOI: 10.1093/ANNONC/MDW316 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus